All Categories
Insulin Icodec, Recombinant

Insulin Icodec, Recombinant

Home >  Modality  >  Proteins  >  Insulin for Human  >  Insulin Icodec, Recombinant

Modality

Insulin Icodec, Recombinant

Description Of Insulin Icodec, Recombinant

Insulin Icodec is chemically named LysB29(icosanedioic acid) A14E, B16H, B25H, desB30 human insulin analog. It is a long-acting basal human insulin given subcutaneously once a week.

Insulin icodec was developed by Novo Nordisk, and approved in 2024, under the brand name Awiqli, for glycemic control in diabetes mellitus patients.

Synonyms

Awiqli, IA287, Insulin Icodec, CAS 1188379-43-2

Amino Acid Sequence of Insulin Icodec

Expression System of Insulin Icodec

Brand Name

Active Substance

Expression System

Awiqli

Insulin Icodec

Yeast (Saccharomyces cerevisiae)

Formulation of Insulin Icodec

Inactive ingredients (Excipients) in Awiqli (Prefilled Cartridge)

Glycerol, metacresol, phenol, sodium chloride, water for injection and zinc acetate.

Yaohai Bio-Pharma Offers One-Stop CDMO Solution for Insulin
Get a Free Quote

Get in touch